Paolo Marzullo

Paolo Marzullo

Auto-generated profile, based on publicly available information

Paolo Marzullo

Department of Nuclear Medicine, Fondazione Toscana “Gabriele Monasterio”, Via Moruzzi 1, Pisa 56124, Italy

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2021 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
Maria Filomena SantarelliMaria Filomena Santarelli
Maria Filomena Santarelli
DGDario Genovesi
Dario Genovesi
Vincenzo PositanoVincenzo Positano
Vincenzo Positano
MSMichele Scipioni
Michele Scipioni
GVGiuseppe Vergaro
Giuseppe Vergaro
PMPaolo Marzullo
Paolo Marzullo

1 July 1997 in JACC
Verified
Journal Article
Closed access
MTMarco Antonio Rodrigues Torres
Marco Antonio Rodrigues Torres
EPEugenio Picano
Eugenio Picano
GPGuido Parodi
Guido Parodi
RSRosa Sicari
Rosa Sicari
FVFabrizio Veglia
Fabrizio Veglia
OPOberdan Parodi
Oberdan Parodi

1 March 2016 in Medicine
Verified
Journal Article
Open access
AGAssuero Giorgetti
Assuero Giorgetti
GPGiovanni Pallabazzer
Giovanni Pallabazzer
ARAndrea Ripoli
Andrea Ripoli
BSBiagio Solito
Biagio Solito
DGDario Genovesi
Dario Genovesi
SSStefano Santi
Stefano Santi
To investigate the prognostic value of tumor metabolism measurements on serial 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and computed tomography scans in patients with locally advanced esophageal cancer undergoing neoadjuvant chemoradiotherapy. Forty-five patients (63 ± 7 years, 6 female) treated with concomitant chemoradiotherapy before surgery were followed up for 24 ± 18 months (range 4–71). Positron emission tomography and computed tomography scans were obtained within 1 week before the start (PET1) and 1 month after the completion of the treatment (PET2). Total body tumor metabolic activity was measured as the sum of the parameters: SUVmax, SUV corrected for lean body mass, and total lesion glycolysis (TLG40/50/70%). Then, delta values for the parameters between PET1 and PET2 were calculated and expressed as percentage of PET1 results. At the time of the analysis, 27 patients were dead and 18 were alive. There was no difference between the 2 groups in terms of age, sex, site of the disease, histology, and the presence/absence of linfonodal metastases (P = NS). Survival random forest analysis (20,000 trees) resulted in an estimate of error rate of 36%. The nonparametric approach identified ΔTLG40 as the most predictive factor of survival (relative importance 100%). Moreover, T (17%), N (5%), and M (5%) stage of the disease, cancer histology (11%), TLG70 (5%) at the end of chemioradioterapy, and ΔTLG50–70 (17%–5%) were positively associated with patient outcome. The nonparametric analysis confirmed the prognostic importance of some clinical parameters, such as TNM stage and cancer histology. Moreover, ΔTLG resulted to be the most important factor in predicting outcome and should be considered in risk stratification of patients treated with neoadjuvant chemoradiotherapy.

10 March 2016 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
AGAlessia Gimelli
Alessia Gimelli
IRIlaria Rovai
Ilaria Rovai
RLRiccardo Liga
Riccardo Liga
EPEmilio Maria Pasanisi
Emilio Maria Pasanisi
PMPaolo Marzullo
Paolo Marzullo

1 May 2021 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
Maria Filomena SantarelliMaria Filomena Santarelli
Maria Filomena Santarelli
MSMichele Scipioni
Michele Scipioni
DGD. Genovesi
D. Genovesi
AGA. Giorgetti
A. Giorgetti
PMP. Marzullo
P. Marzullo
Luigi LandiniLuigi Landini
Luigi Landini
The idea that performing a proper succession of imaging tests and techniques allows an accurate and early diagnosis of cardiac amyloidosis, avoiding the need to perform myocardial biopsy, is becoming increasingly popular. Furthermore, being imaging techniques non-invasive, it is possible to perform the follow-up of the pathology through repeated image acquisitions. In the present review, the various innovative imaging methodologies are presented, and it is discussed how they have been applied for early diagnosis of cardiac amyloidosis (CA), also to distinguish the two most frequent subtypes in CA: immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR); this allows to perform the therapy in a targeted and rapid manner.

2 March 2022 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
PDF file
TSTiziana Sampietro
Tiziana Sampietro
FSFrancesco Sbrana
Francesco Sbrana
BPBeatrice Dal Pino
Beatrice Dal Pino
FBFederico Bigazzi
Federico Bigazzi
ARAndrea Ripoli
Andrea Ripoli
AGAlessia Gimelli
Alessia Gimelli
Tiziana Sampietro, MD, Francesco Sbrana, MD, Beatrice Dal Pino, MD, Federico Bigazzi, PhD, Andrea Ripoli, PhD, Paolo Marzullo, MD, Alessia Gimelli, MD; Coronary